Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Cash & Equivalents: 2021-2025

Historic Cash & Equivalents for Roivant Sciences (ROIV) over the last 5 years, with Mar 2025 value amounting to $2.7 billion.

  • Roivant Sciences' Cash & Equivalents fell 36.84% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 36.84%. This contributed to the annual value of $2.7 billion for FY2025, which is 58.19% down from last year.
  • According to the latest figures from FY2025, Roivant Sciences' Cash & Equivalents is $2.7 billion, which was up 36.41% from $2.0 billion recorded in FY2024.
  • In the past 5 years, Roivant Sciences' Cash & Equivalents registered a high of $6.7 billion during FY2023, and its lowest value of $1.5 billion during FY2022.
  • Moreover, its 3-year median value for Cash & Equivalents was $2.7 billion (2025), whereas its average is $3.9 billion.
  • As far as peak fluctuations go, Roivant Sciences' Cash & Equivalents spiked by 338.64% in 2023, and later tumbled by 70.29% in 2024.
  • Yearly analysis of 5 years shows Roivant Sciences' Cash & Equivalents stood at $2.1 billion in 2021, then reached $2.2 billion in 2021, then rose by 0.26% to $2.1 billion in 2022, then slumped by 31.02% to $1.5 billion in 2022, then dropped by 18.62% to $1.7 billion in 2023, then spiked by 338.64% to $6.7 billion in 2023, then skyrocketed by 287.34% to $6.5 billion in 2024, then crashed by 70.29% to $2.0 billion in 2024, then crashed by 58.19% to $2.7 billion in 2025.